Open Nav

Susavion Biosciences, Inc.

  • J. Kenneth Hoober, Susavion Biosciences, Inc.

Investment or acquisition

  • Date:Wednesday, October 17
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Susavion Biosciences provides the oncology community with novel tetravalent peptides that mimic sugars that activate the host immune system in a non-adjuvant, non-antigenic context. These peptides target immune cell pathways that direct tumor-specific killing either alone or as combination therapies. Primary mechanism(s) of action have been determined to modulate dendritic cells and macrophage populations. Our mission is to apply our technology platform to develop novel drugs that harness the power of the immune system to combat cancer and other major diseases. We developed a portfolio of therapeutic peptides that mature, activate and expand the immune cell repertoire and have achieved “proof of concept” in multiple preclinical oncology models demonstrating a strong immune response validating the technology platform. Current focus is on cancer of peritoneal organs, specifically ovarian cancer.
  • Company
  • Company HQ City:Tempe
  • Company HQ Country:United States
  • Company HQ State:Arizona                        
  • CEO/Top Company Official:Laura L. Eggink, Ph.D., President
  • Year Founded:2006
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :sv6D
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :Three
  • Previous and Current Investors:Richard Rockefeller, Pam Omidyar, Carol Ward, Jack Waller, J.K. Hoober
  • Size of Last Investment Round:100,000
  • Total Amount Raised to Date, In All Rounds:4.2 M
J. Kenneth Hoober
Susavion Biosciences, Inc.